Pharma channel feed – Endpoints News

Pharma channel feed

The next Emflaza: Acer Therapeutics looks to take a page out of Marathon's book

8 years ago

Insider trading scam spurred by $11.2B Gilead deal earns a stretch in prison

8 years ago

Novartis ties a new round of biosimilar development programs to a partnership deal with India's Biocon

8 years ago

Tired of being gouged for old, cheap therapies, a consortium of hospitals is going into the drug business — NYT

8 years ago

With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK

8 years ago

FDA and Pentagon forge breakthrough designation agreement

8 years ago

Merck KGaA taps UK cancer research organizations to feed pipeline

8 years ago

After a bruising year, Aeterna Zentaris inks a $24M upfront US pact for growth hormone asset

8 years ago

Kymriah gets speedy reviews in US and EU as Novartis looks to swiftly expand CAR-T indications

8 years ago

FDA commissioner Scott Gottlieb just broke a public promise on publishing CRLs — and yes, it matters

8 years ago

Developers are laying the foundation for a new biotech complex in California

8 years ago

Scoop: With its NDA in limbo, Ironshore execs shuttered the ADHD biotech

8 years ago

Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18

8 years ago

In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer

8 years ago

The Cambridge siren call: Philips NV moving HQ to mega-project Cambridge Crossing

8 years ago

Headed for a blockbuster smash, Roche picks up another key OK for landmark MS drug Ocrevus

8 years ago

Genentech beefs up its PD-L1 combo pipeline, signing the 'don’t eat me' specialists at Forty Seven

8 years ago

New study looks at FDA's use of social media to communicate on drug safety

8 years ago

Genentech adds a new program for Syndax’s lead cancer drug to its Tecentriq combo platform

8 years ago

On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product profitability

8 years ago

After bumpy 2017, Celgene CEO says taking risk is the only way forward

8 years ago

Sanofi, Regeneron up the ante on PD-1 I/O program by a billion dollars

8 years ago

Teva inks $200M global licensing deal with migraine rival Alder

8 years ago

Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran

8 years ago

First page Previous page 305 306 307308309 310 311 Next page Last page